Navigation Links
KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
Date:4/6/2011

NEW YORK, April 6, 2011 /PRNewswire/ -- KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has signed an exclusive agreement with AdnaGen, a wholly-owned subsidiary of Alere, Inc., to license specific antibodies. Under the agreement, KellBenx will have exclusive worldwide rights to commercialize the antibodies, which enable the extraction of clinically relevant information from maternal blood through a test that could be widely available as early as 2012.

Fetal Nucleated Red Blood Cells (FNRBCs), which have been identified in maternal blood, can be a source for monitoring and diagnosis of maternal, fetal, and neo-natal health and disease. The KellBenx process involves the enrichment of these FNRBCs with the antibodies licensed from AdnaGen to perform chromosomal or genetic analysis to identify markers of potential disorders. With these antibodies, known as Monoclonal Antibodies with Specificity for Fetal Erythroid Cells, KellBenx will be able to launch clinical trials of its non-invasive test.

"We are delighted to secure a license that allows KellBenx to use the AdnaGen antibodies," said Hassan Bennani, MD., CEO of KellBenx. "This agreement creates the opportunity to begin clinical testing of the exciting laboratory results we have produced over the past year, and it brings us one step closer to bringing a non-invasive prenatal blood test to the market that can detect genetic disorders."

"We're pleased to be able to help KellBenx advance a technology that could have a profound impact on the detection and diagnosis of fetal and neonatal genetic disorders," said Alexander L. Weis, Managing Director of AdnaGen AG. "Our proprietary antibodies will enable the clinical tests that could make this non-invasive testing a reality."

About KellBenx

Founded in 2010, KellBenx, Inc. is a privately-held biotechnology company based in New York City. KellBenx is developing high value, innovative tests that leverage the ability to extract clinically relevant information from blood.  Our focus is to improve women's healthcare and one of our first tests is in the area of non-invasive prenatal diagnosis (NIPD) for genetic disorders. For more information, please call 631-643-2614 or visit kellbenx.com.


'/>"/>
SOURCE KellBenx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
2. Core Essence Secures $11.5 Million Series B Financing
3. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
4. Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
5. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
6. PLC Systems Secures $4 Million in Financing
7. Biomatrica Secures Strategic Investment from IQT
8. Digital Assent Secures $2 Million Series A Financing to Grow PatientPad Point-of-Care Network
9. TechniScan Secures $10 Million Equity Financing Facility
10. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
11. MedShape Solutions, Inc. Secures Investment From IQT to Support U.S. Intelligence Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 New England Pediatric Device Consortium (NEPDC) ... including funding and in-kind service towards the commercialization of ... "Making blood draws less traumatic for children could ... experience better.  We,re looking forward to working with Velano ... care for the kids we treat," said Ann-Christine ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... Demand Forecast to 2022" report to their offering. ... The global wound care market was worth ... CAGR of 6.7% during 2016-2022 Among the various wound care ... in the global market in 2015. Among the various applications, surgical wound ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental ... ... markets for Dental Implants in US$ Million. The report provides separate comprehensive ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
(Date:3/24/2017)... ... 24, 2017 , ... In just two days, Aqua Design ... garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the original ... (and counting) already backing the campaign. , “We are very grateful for ...
(Date:3/24/2017)... ... 2017 , ... Northridge dentists, Dr. Michel Elyson ... apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has long ... is increasingly being treated at dental offices with newly developed procedures and appliances. ...
(Date:3/24/2017)... ... 24, 2017 , ... The law firm of Enea, Scanlan & Sirignano, ... Westchester resident Lauren C. Enea has joined the firm as an associate attorney. Ms. ... practice in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. ...
(Date:3/24/2017)... Miami, FL (PRWEB) , ... March 24, 2017 ... ... HyGIeaCare Inc. ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy ... Health Endoscopy Centers in 87th Ave., Miami, FL. , The ...
Breaking Medicine News(10 mins):